Ionis Pharmaceuticals, Inc. Shareholders' Equity
Ionis Pharmaceuticals, Inc. (IONS) had Shareholders' Equity of $439.74 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-29
- 2026-06-30: Stockholders' Equity Attributable to Parent $439.74M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $491.41M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $489.09M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $617.97M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $439.74M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $491.41M 10-Q · filed 2026-07-29 | |
| 2025-12-31 | $489.09M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $617.97M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $631.72M 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $475.73M 10-Q · filed 2026-07-29 | |
| 2024-12-31 | $588.35M 10-Q · filed 2026-07-29 | |
| 2024-09-30 | $662.47M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $263.70M 10-Q · filed 2025-10-29 | |
| 2024-03-31 | $296.51M 10-Q · filed 2025-07-30 | |
| 2023-12-31 | $386.69M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $315.46M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $428.30M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $486.57M 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $572.89M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $594.36M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $624.73M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $709.57M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $771.74M 10-K · filed 2025-02-19 | |
| 2021-09-30 | $530.54M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $582.67M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $680.56M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $743.28M 10-K · filed 2024-02-21 | $843.35M 10-K · filed 2021-02-24 |
| 2020-09-30 | $1.38B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.38B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.36B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.47B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $1.34B 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.27B 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $1.21B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.05B 10-K · filed 2020-03-02 | |
| 2018-09-30 | $710.55M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $696.25M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $301.39M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $281.01M 10-K · filed 2019-03-01 | $330.87M 10-K · filed 2018-02-28 |
| 2017-09-30 | $307.97M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $215.57M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $201.81M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $99.56M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $139.64M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $111.21M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $158.16M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $200.79M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $245.41M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $300.32M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $275.85M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $257.78M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $344.77M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $366.86M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $374.10M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $378.39M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $401.45M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $401.08M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $201.09M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $182.77M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $170.28M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $154.31M 10-Q · filed 2012-08-06 | |
| 2012-03-31 | $150.87M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $171.43M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $186.82M 10-Q · filed 2011-11-08 | |
| 2010-12-31 | $244.54M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $253.71M 10-Q · filed 2010-11-05 | |
| 2010-06-30 | $262.23M 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $291.72M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |